• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rectal administration of baclofen at the end of life
Spasticity can be a complicating symptom of a variety of neurological conditions such as multiple sclerosis, motor neuron disease, Creutzfeldt-Jakob disease, or post-stroke. Several pharmacological treatment options are available, including baclofen, tizanidine, gabapentin, botulinum toxin A and tetrahydrocannabinol/canabidiol (1, 2). However, treatment feasibility decreases as the end of life approaches, e.g. when patients are no longer able to tolerate oral medications, the onset of action would be too long, or the initiation of parenteral drug therapy (intravenous, intrathecal) is no longer indicated or appropriate.
Source: Journal of Pain and Symptom Management - August 7, 2018 Category: Palliative Care Authors: Charlotte Selge, Claudia Bausewein, Constanze Remi Source Type: research

Subcutaneous Use of Baclofen
Painful spasticity is an often debilitating symptom that occurs mostly in patients with neurologic diseases such as multiple sclerosis or stroke. Treatment approaches include pharmacologic and nonpharmacologic interventions. Baclofen is one of the drugs commonly used to decrease elevated muscle tone. This GABAB agonist acts primarily by limiting the release of excitatory neurotransmitters on the spinal level, thereby decreasing spastic muscle tone. Baclofen is licensed for oral and intrathecal use in spasticity. The abrupt cessation of baclofen therapy can lead to withdrawal syndromes including epileptic seizures. Here, we...
Source: Journal of Pain and Symptom Management - May 30, 2014 Category: Palliative Care Authors: Constanze Rémi, Elisabeth Albrecht Tags: Letters Source Type: research